10 explain how biopharmaceuticals can be created using plants. Ideas

Contents

Below is information and knowledge on the topic explain how biopharmaceuticals can be created using plants. gather and compiled by the show.vn team. Along with other related topics like: explain how trees help maintain air quality., compare the relationship of trees with other plants and with insects., how has human use of trees had both a positive and negative impact?, approximately how many plant made pharmaceuticals are currently under different stages of discovery?, which of the following statements about human impact on trees is true?, the fruit of trees is the only part that is used by humans for food., every year one hundred trees remove approximately _______ from the atmosphere., which of the following is not a way in which trees benefit the environment?.


ing – 0.307

Print this fact sheet

by P. Byrne1 (4/08)

Quick Facts…

  • Bio-pharming is the production of pharmaceutical proteins in genetically engineered plants.
  • Pharmaceuticals can be made in plants at a significantly reduced cost compared to current production methods.
  • Major concerns with bio-pharming are that food or feed crops may become contaminated with pharmaceutical products, and that the products may have negative effects on natural ecosystems.
  • Bio-pharm crops are regulated by two federal agencies (USDA and FDA) and by state departments of agriculture.

Manufacturing pharmaceutical products in crops has been one of the promised benefits of plant genetic engineering for the past 20 years. This use of biotechnology, sometimes known as “pharming,” “bio-pharming,” or “molecular farming,” has migrated from speculation to the
testing phase in fields and greenhouses across the country. Bio-pharming promises more plentiful and cheaper supplies of pharmaceutical drugs, including vaccines for infectious diseases and therapeutic proteins for treatment of such things as cancer and heart disease. “Plant-made pharmaceuticals” (PMPs) are produced by genetically engineering plants to produce specific compounds, generally proteins, which are extracted and purified after harvest. As used here, the terms bio-pharming and PMP do not include naturally occurring plant products or nutritionally enhanced foods.

How are biotech drugs currently manufactured?

Many protein-based drugs are currently produced in sterile fermentation facilities by genetically engineered microorganisms or mammalian cell cultures in stainless steel tanks (Felsot, 2002). Because these fermentation plants have huge capital construction costs, industry has been unable to keep up with the growing demand. For example, the biotech company Amgen is reportedly unable to meet demand for Enbrel, a protein-based arthritis medicine made in mammalian cell cultures (Alper, 2003). Another method for obtaining biopharmaceuticals is to extract them from animal and human tissues (e.g., insulin from pig and cow pancreas, or blood proteins from human blood (Freese, 2002)). However, these are high-cost procedures that carry the risk of transmitting  infectious diseases to humans. Due to advances in plant genetic engineering over the past two decades, plants can now be modified to produce a wide range of proteins. It is hoped this will result in therapeutic products at a price significantly cheaper than through current methods. For example, antibodies that currently cost thousands of dollars per gram might be produced in plants for $200 per gram (Ohlrogge and Chrispeels, 2003).

What pharmaceuticals could be made in plants?

For the near-term, PMPs will be proteins because proteins are directly encoded by genes. This property makes their production through genetic engineering more straightforward than other types of biochemical compounds that are synthesized via more complex methods. See Table 1 for examplesof potential bio-pharm products.

Table 1. Potential plant-made pharmaceuticals. Information compiled from Canadian Food  Inspection Service (2001), Ohlrogge and Chrispeels (2003), and the Web sites of the Biotechnology Industry Organization (www.bio.org), and Ventria Bioscience (www.ventria.com).
Product Definition Examples
Antibodies Specialized proteins of the immune system that initiate the body’s
defense response.
Specific antibodies may be developed to fight cancer, HIV-AIDS,
hepatitis, malaria, dental caries, and other diseases.
Antigens (vaccines) Compounds that elicit the production of antibodies that protect
against disease.
Plant-made vaccines are currently under development for protection
against cholera, diarrhea (Norwalk virus), and hepatitis B.
Enzymes Proteins that catalyze biochemical reactions. Enzymes could be used both to treat and to diagnose disease. For
example, lipase is an enzyme that breaks down dietary fats and is
used to treat symptoms of cystic fibrosis and other diseases.
Hormones Chemical messengers active at low concentrations and produced in
specialized cells.
Insulin is produced in the pancreas and helps regulate sugar metabolism.
Diabetics with insulin deficiencies must replace it via shots or pumps.
Structural proteins Proteins that provide structural supportto cells or tissues. Collagen is a structural protein found in animal connective tissues
and used in cosmetics.
Anti-disease agents A wide variety of proteins. The anti-infection proteins interferon and lactoferrin, and aprotinin
(which controls blood loss during surgery) have been engineered in
plants.

What crops are being considered for pharmaceutical production?

The most common PMP crops grown in U.S. field trials are corn, tobacco, and rice. Other crops being investigated include alfalfa, potato, safflower, soybean, sugarcane, and tomato. Suitable host plants must be easily engineered, capable of high levels of protein production, and have appropriate procedures for extracting the PMP from plant tissues. Knowing the  agronomy, physiology, pests, and diseases of a crop is also an advantage. Ideally, the host plant is a non-food crop that does not have wild relatives in the production environment, and could not survive in the environment from seeds carried by wind or wildlife. When food crops are used,  complete pollen sterility is desired, since it would prevent nearby fields of the crop from being pollinated by the bio-pharm crop. While this is not yet technically feasible, using self-pollinating crops or male-sterile crops can minimize pollination of food crops.

Read More:  10 why doesn't the mississippi river mix with the gulf of mexico Ideas

What part of the plant produces the PMP?

Most bio-pharming applications target production and storage of the pharmaceutical protein in seeds, which naturally accumulate high concentrations of proteins and oils. Seeds are also the easiest part of the plant to store and transport to processing facilities. To achieve production of
the pharmaceutical protein in seeds, seed-specific “promoters” (regulatory elements of genes that control how much of a gene product is made and where in the plant it is synthesized) are engineered into the plant. Two seed-specific promoters used in experimental bio-pharm lines are the beta-phaseolin promoter of common bean and the oleosin promoter of Brassica species (Moloney, 2000). The location of protein accumulation within the cell is also important to ensure correct folding and stability of the protein (Moloney, 2000).

While synthesis of biopharmaceuticals in seeds has many advantages, not all PMPs will be produced there. Leaves are the target tissues in some alfalfa and tobacco applications, and tubers are targeted in potato production systems (Canadian Food Inspection Service, 2001). A variation of PMP technology involves infecting plants with viruses that are engineered with the gene for the pharmaceutical protein. Upon infection (for example, of tobacco leaves), the plant’s cellular machinery produces the biopharmaceutical along with other viral proteins (Freese, 2002).

How will PMPs be produced?

To be successful, pharmaceutical production in plants must be a highly sophisticated and closely regulated enterprise, and will differ from conventional crop production in many ways. Bio-pharm crops must be grown, transported, and processed using safeguards designed to ensure a consistent, high-quality product and to prevent inadvertent mixing with food crops and other negative consequences. To achieve this goal, a “closed loop identity preservation” system is envisioned, in which the crop is carefully regulated and monitored from planting to harvest to pharmaceutical extraction (Felsot, 2002). Seed will be available only to trained contract growers, and the harvested product will be delivered in sealed containers to the processing facility.
Standard operating procedures developed for each specific PMP crop will govern isolation distances from conventional crops, equipment use, and field inspections during the growing season and for at least a year afterward. Meticulous record-keeping will be required at each step of the process.

When will plant-made pharmaceuticals reach the market?

Research on PMP crops has been ongoing for many years in laboratories, greenhouses, and field trials. In 2002, PMP crops were grown at 34 field sites totaling 130 acres in the U.S. Three PMPs currently undergoing evaluation in clinical trials are designed to target non-Hodgkins lymphoma, cystic fibrosis, and E. coli/traveler’s diarrhea (Biotechnology Industry Organization). Assuming their effectiveness and safety are demonstrated and environmental concerns are adequately addressed, therapuetic pharmaceuticals from plants may reach the market in the second half of this decade.

Who is doing bio-pharming?

Among the companies pursuing commercial development of PMPs are Dow AgroSciences, Meristem Therapeutics, and Ventria Bioscience. Reflecting the commercial uncertainty of the industry, some companies, including Monsanto, have discontinued development of PMP products, and the biopharmaceutical firms CropTech and Large Scale Biology Corp. have filed for bankruptcy in recent years. The companies that develop PMPs will most likely contract with a limited number of highly skilled farmers to produce bio-pharm crops.

What are the benefits of plant-made pharmaceuticals?

  • PMPs can be produced at a significantly reduced cost compared to current production methods. Therefore, the technology has the potential to benefit medical patients by providing a more affordable source of vaccines and other pharmaceuticals. However, it is not clear how large the cost reduction will be or how much of the savings will be passed on to consumers.
  • Plants can be engineered to produce proteins of greater complexity than is possible with microorganisms (Collins, 2003), and to produce proteins that cannot be produced in mammalian cell cultures (Anonymous, 2002).
  • A limited number of growers and production workers will likely benefit economically from this new agricultural enterprise. The number of acres required to produce a year’s worth of a given pharmaceutical will likely be quite small compared to crop acreage for food and feed use.

What are the risks of plant-made pharmaceuticals?

Risks are not uniform for all bio-pharm applications, but will vary depending on the nature of the pharmaceutical product, the crop and tissues in which the PMP is produced, and the environment in which the crop is grown. The potential risk factors of PMPs are summarized below.

  • Pollen from plants engineered to produce pharmaceuticals may fertilize nearby food or feed crops of the same species. If this occurs, the pharmaceutical may be produced in seed of the neighboring crop, with potentially negative effects on human or animal consumers of the seed and on crop markets. The risk of gene flow via pollen drift is greater in cross-pollinated crops like corn. Methods to minimize this risk include spatial and temporal isolation, the use of male sterility (i.e., plants that don’t produce viable pollen), and in the case of corn, detasseling (removing tassels before they shed pollen). When male sterility or detasseling are used, fertile male plants that lack the gene for the pharmaceutical are planted in the field to provide the pollen source.
  • Commingling of PMP crops and food or feed crops may occur. This could happen through improper labeling, mixing of seed in planting, harvesting, transportation, or processing equipment, or the presence of “volunteer” PMP plants in subsequent seasons in the same field. In a 2001 case, ProdiGene failed to eliminate volunteer bio-pharm corn plants from a soybean crop planted later in the same field as the PMP corn (Fox, 2003). The company was fined $250,000 by USDA and was required to reimburse the government $3 million for expenses related to destruction of 500,000 bushels of potentially contaminated soybeans.
  • The introduced gene or its product may have negative effects on the natural environment. For example, wildlife feeding on the crop may ingest harmful levels of the PMP, or soil micro-organisms may be inhibited by decomposing crop residue or substances exuded from roots of PMP plants.
  • Farm workers may be exposed to unhealthy levels of a biopharmaceutical by absorbing products from leaves through their skin, inhaling pollen, or breathing in dust at harvest.
  • Unexpected toxins or residues of pesticides used on the crop may contaminate the final drug product.

What steps are being taken to prevent or reduce these risks?

Workers in training.
All workers involved with PMP crop production must participate annually in an APHIS-approved  training program on the required procedures for growing these crops. Photo courtesy of USDA.
Equipment for planting and harvesting bio-pharm crops.
Equipment for planting and harvesting of bio-pharm crops must be dedicated to that purpose, i.e., the equipment cannot be used with any other crop. Photo courtesy of USDA.
Tractors and tillage equipment.
Tractors and tillage equipment must be thoroughly cleaned before being used with other crops. Photo courtesy of USDA.
Worker monitoring bio-pharm crop.
Bio-pharmed fields will be closely monitored during the growing season and in following seasons to ensure that required procedures are being followed and that volunteer plants are found and disposed of properly. Photo courtesy of USDA.
Sample bio-pharm test site.
Test sites must provide the required isolation distances from other fields of the same crop. For example, bio-pharm corn must be isolated by at least 1 mile from other corn fields if it is open-pollinated, and by 1/2 mile if pollination is controlled through male sterility or detasseling.

Because bio-pharm crops are genetically engineered, they are subject to U.S. federal regulations that govern all such crops. Three federal agencies, the U.S. Department of Agriculture – Animal and Plant Health Inspection Service (APHIS), the Food and Drug Administration (FDA), and the Environmental Protection Agency (EPA) all play roles in regulating genetically engineered crops, though their specific responsibilities vary depending on the type of application involved.

Besides the standard regulations that apply to all genetically engineered crops, bio-pharm crops are subject to additional regulatory oversight. One major difference between PMP crops and  enetically engineered food crops is that the former require perpetual permitting by APHIS, whereas the latter crops, once approved by the three federal agencies, are considered “unregulated” and are freely available through commercial channels without permits. In September, 2002, FDA and USDA issued the draft document “Guidance for Industry: Drugs, Biologics, and Medical Devices Derived from Bioengineered Plants for Use in Humans and Animals”, https://www.federalregister.gov/documents/2002/09/12/02-23105/draft-guidance-for-industry-drugs-biologics-and-medical-devices-derived-from-bioengineered-plants. In 2003, APHIS announced its intentions to impose more stringent conditions for field tests of genetically engineered crops that produce pharmaceutical or industrial compounds. The objective of the new regulations is to prevent contamination of food and feed crops with the biopharmaceuticals and to minimize environmental impacts. In 2004, APHIS provided additional guidance for bio-pharm permit applicants (APHIS, 2004). For example, applicants are requested to provide details on the amount of the gene product in all plant parts, the results of allergenicity testing, and an assessment of potential toxicity to non-target organisms.

Read More:  10 the most common reason that dew forms is . Ideas

FDA has the responsibility to ensure the safety and usefulness of drugs. Therefore, clinical trials and marketing of PMPs will require FDA approval. FDA will also oversee procedures for  manufacturing PMPs to guarantee consistent product quality and potency.

EPA regulates the environmental effects of proteins engineered for pest resistance (such as Bt insecticidal proteins) in a PMP crop. However, EPA does not review environmental effects of bio-pharm crops at this time.

The department of agriculture of the state in which a PMP crop field test is proposed, is given the opportunity to review APHIS’ preliminary assessment of applications for field testing of genetically engineered crops. In the past, this has been a routine approval, but with PMP crops, states are taking a more cautious approach. State departments of agriculture may request additional permit conditions beyond those imposed by APHIS.

Are bio-pharm crops likely to be grown in Colorado?

The advantages Colorado has for bio-pharming are the ease of achieving recommended isolation distances for many crops, and the ability to obtain high yields under irrigated conditions with  relatively little disease and insect pest pressure.

The French company Meristem Therapeutics applied to APHIS for a permit to grow a field test of PMP corn in Phillips County, Colorado in 2003. To assist with evaluation of this and future permit applications for PMP crops, the Colorado Department of Agriculture (CDA) formed a Technical
Advisory Committee to evaluate the adequacy of conditions for gene containment and for minimizing environmental impact. Although the Meristem application was approved, the company decided not to plant the trial because the optimum planting date had passed.

In 2004, APHIS and CDA approved an application from an Iowa State University researcher to grow bio-pharm corn, and a small field plot was planted in Logan County. Whether commercial scale bio-pharm production will occur in Colorado depends on a number of business and government policy decisions, the outcomes of which are difficult to predict at present.The Colorado Institute of Public Policy has examined the issues involved in bio-pharming and published the report “Bio-Pharming in Colorado: A Guide to Issues for Making Informed Choices” (https://mountainscholar.org/handle/10217/185447).

Final Thoughts

Like many other aspects of crop biotechnology, supporters and critics of PMP crops differ strongly over the benefits and risks of this new application. Proponents stress the societal benefits of a cheaper and more plentiful source of pharmaceuticals, while opponents emphasize the risks of contamination of the food supply and unknown effects on ecosystems. Given the uncertainties
surrounding bio-pharm crops, it is difficult to predict whether and to what extent this technology will become part of our future agricultural and health care systems. Several questions remain to be answered, including: (1) Are PMPs safe and effective medicines for humans and animals? (2) Will production costs of PMPs, especially for the purification process, be reduced sufficiently to bring the promised economic benefits? (3) What will be the appropriate combinations of crop species, plant parts, growing environments, and production safeguards that will provide acceptable levels of gene containment and environmental protection? (4) Are our regulatory structures adequate to the task of regulating and monitoring bio-pharm crops, and, if not, what changes will be necessary? (5) To what extent will crop-based pharmaceuticals provide new economic opportunities for farmers and rural communities?

References

Alper, J. 2003. Hatching the golden egg: A new way to make drugs. Science 300:729-730.

Anonymous, 2002. Pharming the Field: A look at the benefits and risks of bioengineering plants to produce pharmaceuticals. The Pew Charitable Trusts. www.pewtrusts.org/our_work_report_detail.aspx?id=35424.

APHIS, 2003. USDA strengthens 2003 permit conditions for field testing genetically engineered plants. Press release. https://www.aphis.usda.gov/brs/fedregister/BRS_20030806a.pdf.

APHIS. 2004. Updated guidance on bioengineered plants for producing pharmaceuticals or industrial products for applicants developing these plants for release (January 2004).

Canadian Food Inspection Service. 2001. Plant molecular farming discussion document.

Collins, S. 2003. Potato the medical factory of tomorrow. The New Zealand Herald, April 4, 2003.

Felsot, A. 2002. Pharm farming. Agrichemical and Environmental News, no. 195, July 2002, http://aenews.wsu.edu.

Fox, J.L. 2003. Puzzling industry response to Prodigene fiasco. Nature Biotechnology 21: 3-4.

Freese, B. 2002. Manufacturing drugs and chemical crops: Biopharming poses new threats to consumers, farmers, food companies and the environment.
https://www.jstor.org/stable/resrep00065.6#metadata_info_tab_contents.

Moloney, M.M. 2000. Molecular farming using seeds as hosts. pp. 226-253. M. Black and J.D.Bewley (eds.) Seed technology and its biological basis. CRC Press, Boca Raton, FL.

Ohlrogge, J., and M.J. Chrispeels. 2003. Plants as chemical and pharmaceutical factories. pp. 500-527. M.J. Chrispeels and D.E. Sadava (eds.) Plants, genes, and biotechnology. Jones and Bartlett Publishers, Sudbury, MA.

Websites for Additional Information

The Union of Concerned Scientists https://www.ucsusa.org/resources/protecting-food-supply-era-pharmaceutical-and-industrial-crops discusses benefits and risks of pharm crops.

The Biotechnology Industry Organization, https://archive.bio.org/articles/plant-made-pharmaceuticals-background-and-key-points, has a number of fact on plant-made pharmaceuticals.

The Transgenic Crops website, http://cls.casa.colostate.edu/TransgenicCrops/what.html,
contains introductory information on the techniques and regulation of plant genetic engineering.

1 P. Byrne, Colorado State University Extension agronomy specialist and associate professor, department of soil and crop sciences. 7/03. Revised 4/08.

Colorado State University, U.S. Department of Agriculture and Colorado counties cooperating. CSU Extension programs are available to all without discrimination. No endorsement of products  mentioned is intended nor is criticism implied of products not mentioned.

Go to top of this page.

Extra Information About explain how biopharmaceuticals can be created using plants. That You May Find Interested

If the information we provide above is not enough, you may find more below here.

Bio-pharming – 0.307 – CSU Extension

Bio-pharming – 0.307 - CSU Extension

  • Author: extension.colostate.edu

  • Rating: 3⭐ (210444 rating)

  • Highest Rate: 5⭐

  • Lowest Rate: 2⭐

  • Sumary: Bio-pharming is the production of pharmaceutical proteins in genetically engineered plants. Pharmaceuticals can be made in plants at a significantly reduced cost compared to current production methods. Major concerns with bio-pharming are…

  • Matching Result: Bio-pharming is the production of pharmaceutical proteins in genetically engineered plants. Pharmaceuticals can be made in plants at a significantly reduced …

  • Intro: Bio-pharming – 0.307 Print this fact sheet by P. Byrne1 (4/08) Quick Facts… Bio-pharming is the production of pharmaceutical proteins in genetically engineered plants. Pharmaceuticals can be made in plants at a significantly reduced cost compared to current production methods. Major concerns with bio-pharming are that food or feed crops may become contaminated…
  • Source: https://extension.colostate.edu/topic-areas/agriculture/bio-pharming-0-307/

Top Reasons for Using Plants to Make Biologics

Top Reasons for Using Plants to Make Biologics

  • Author: leafexpressionsystems.com

  • Rating: 3⭐ (210444 rating)

  • Highest Rate: 5⭐

  • Lowest Rate: 2⭐

  • Sumary: In this blog we’ll look at the top reasons for using plants to make biologics, and explain the many benefits a plant-based system can offer.I

  • Matching Result: In this blog we’ll look at the top reasons for using plants to make biologics, and explain the many benefits a plant-based system can offer.

  • Intro: Top Reasons for Using Plants to Make BiologicsIn this blog we’ll look at the top reasons for using plants to make biologics, and explain the many benefits a plant-based system can offer.Plant-based technologies have existed for the past 30 years, however it is not until recently that their potential for…
  • Source: https://www.leafexpressionsystems.com/reasons-for-using-plants-to-make-biologics/

Transgenic plants as factories for biopharmaceuticals – PubMed

Transgenic plants as factories for biopharmaceuticals - PubMed

  • Author: pubmed.ncbi.nlm.nih.gov

  • Rating: 3⭐ (210444 rating)

  • Highest Rate: 5⭐

  • Lowest Rate: 2⭐

  • Sumary: Plants have considerable potential for the production of biopharmaceutical proteins and peptides because they are easily transformed and provide a cheap source of protein. Several biotechnology companies are now actively developing, field testing, and patenting plant expression systems, while clinic …

  • Matching Result: by G Giddings · 2000 · Cited by 834 — Plants have considerable potential for the production of biopharmaceutical proteins and peptides because they are easily transformed and provide a cheap …

  • Intro: Transgenic plants as factories for biopharmaceuticals – PubMed Review . 2000 Nov;18(11):1151-5. doi: 10.1038/81132. Affiliations PMID: 11062432 DOI: 10.1038/81132 Review Transgenic plants as factories for biopharmaceuticals G Giddings et al. Nat Biotechnol. 2000 Nov. Abstract Plants have considerable potential for the production of biopharmaceutical proteins and peptides because they are easily…
  • Source: https://pubmed.ncbi.nlm.nih.gov/11062432/

Plants as Factories for Human Pharmaceuticals – NCBI – NIH

Plants as Factories for Human Pharmaceuticals - NCBI - NIH

  • Author: ncbi.nlm.nih.gov

  • Rating: 3⭐ (210444 rating)

  • Highest Rate: 5⭐

  • Lowest Rate: 2⭐

  • Sumary: Plant molecular farming (PMF), defined as the practice of using plants to produce human therapeutic proteins, has received worldwide interest. PMF has grown and advanced considerably over the past two decades. A…

  • Matching Result: by J Yao · 2015 · Cited by 231 — Plant molecular farming (PMF), defined as the practice of using plants to produce human therapeutic proteins, has received worldwide …

  • Intro: Plants as Factories for Human Pharmaceuticals: Applications and Challenges Journal List Int J Mol Sci PMC4691069 Int J Mol Sci. 2015 Dec; 16(12): 28549–28565. Chang Won Choi, Academic EditorAbstractPlant molecular farming (PMF), defined as the practice of using plants to produce human therapeutic proteins, has received worldwide interest. PMF has…
  • Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691069/

Read More:  10 what does the first paragraph of the declaration of independence mean Ideas

Plant-Based Biomanufacturing a Growing Trend

Plant-Based Biomanufacturing a Growing Trend

  • Author: genengnews.com

  • Rating: 3⭐ (210444 rating)

  • Highest Rate: 5⭐

  • Lowest Rate: 2⭐

  • Sumary: Plant-based expression (“pharming”) can help the biopharm industry reduce manufacturing costs, scale-up production, and reduce complexity.

  • Matching Result: Plant-based expression (“pharming”) can help the biopharm industry reduce manufacturing costs, scale-up production, and reduce complexity.

  • Intro: Plant-Based Biomanufacturing a Growing Trend Using plant cells to make biopharmaceuticals is not a new idea. Pfizer’s Gaucher disease drug Elelyso (taliglucerase alfa), which is manufactured using carrot cells in culture—was approved in 2012. Whole plants are also used to make biopharmaceuticals. For example, last year, the FDA approved Palforzia…
  • Source: https://www.genengnews.com/topics/bioprocessing/plant-based-biopharmaceuticals-a-growing-trend/

US Regulation of Plant-made Biopharmaceuticals, Part 1

US Regulation of Plant-made Biopharmaceuticals, Part 1

  • Author: biopharminternational.com

  • Rating: 3⭐ (210444 rating)

  • Highest Rate: 5⭐

  • Lowest Rate: 2⭐

  • Sumary: Transgenic plant systems promise lower production costs since plants can be grown in a field instead of a cell-culture facility. Also, they provide an alternative production system for proteins that are difficult to express in cell…

  • Matching Result: Some products that have been produced in plants include trypsin, aprotinin, therapeutic monoclonal antibodies, therapeutic enzymes, protective …

  • Intro: US Regulation of Plant-made Biopharmaceuticals, Part 1Projections for new and existing biopharmaceutical drugs indicate that demand will soon overwhelm supply.1 New facilities housing cell-culture units can be built, but they require a substantial capital investment and are costly to operate. In response, alternative production systems are being developed. One of…
  • Source: https://www.biopharminternational.com/view/us-regulation-plant-made-biopharmaceuticals-part-1

Plants: The Future Pharmaceutical Factory

Plants: The Future Pharmaceutical Factory

  • Author: scirp.org

  • Rating: 3⭐ (210444 rating)

  • Highest Rate: 5⭐

  • Lowest Rate: 2⭐

  • Sumary: The main objective of this study was to identify prospects, advantages and challenges of plant molecular farming. Plant-made pharmaceuticals (PMPs) and plant made vaccines (PMVs) were intended to be used for human consumption. A broad range of plants, including crops, vegetables and fruits have been investigated for their applicability in…

  • Matching Result: by B Sil · 2014 · Cited by 16 — Edible vaccines are developed through the use of biotechnology, but are not necessarily the same as PMPs. PMPs produce proteins that will be used in the …

  • Intro: Plants: The Future Pharmaceutical Factory American Journal of Plant Sciences Vol.5 No.3(2014), Article ID:42672,9 pages DOI:10.4236/ajps.2014.53044 Plants: The Future Pharmaceutical Factory Bipradut Sil*, Sumita Jha Centre of Advanced Study in Botany, University of Calcutta, Kolkata, India.Email: *bipradut@gmail.comCopyright © 2014 Bipradut Sil, Sumita Jha. This is an open access article distributed under…
  • Source: https://www.scirp.org/html/12-2601197_42672.htm

Frequently Asked Questions About explain how biopharmaceuticals can be created using plants.

If you have questions that need to be answered about the topic explain how biopharmaceuticals can be created using plants., then this section may help you solve it.

How can plants be used to make biopharmaceuticals?

Plant-based systems for the production of biopharmaceuticals may be designed as bioreactors, in which case the product is extracted from plant tissues and administered orally or to children, or the plant tissue expressing the biopharmaceutical protein may be used for direct oral delivery.

What do you think the risks are in making pharmaceuticals derived from plants?

Pollen transfer to closely related species, contamination of non-transgenic crops intended for human consumption, allergic reactions to drugs derived from genetically modified plants, and persistence of genetically modified material are some of the potential risks connected with plant-based pharmaceuticals.

What does biotechnology’s biopharming mean?

Biopharming, also referred to as plant molecular farming, is the process of using genetically altered plants to create a variety of pharmaceuticals and commercial goods.

Which of the following best explains why trees are crucial to the health of the atmosphere as a whole?

An acre of mature trees can absorb the CO2 produced by a car traveling 26,000 miles in a year, removing and storing the carbon while releasing the oxygen back into the atmosphere.

Biopharmaceuticals: How are they created?

Production of Biopharmaceuticals Several protein expression systems have been developed over the years, each with benefits and drawbacks. Biopharmaceuticals are produced using recombinant DNA technology to use a host cell to express and secrete therapeutic proteins.

What steps are involved in the production of biopharmaceuticals?

The first such molecule was recombinant human insulin, pioneered by Genentech in 1982. The biopharmaceutical manufacturing process harnesses biosynthesis, which tends to yield far larger, more complex molecules — proteins and nucleic acids — than are typically produced through traditional chemical synthesis.

What role do plants play in the pharmaceutical industry?

Since complementary and alternative medicine (CAM) has traditionally not been taught in medical school, most doctors are probably unaware that an astounding 80% of antibiotics, cardiovascular, immunotherapy, and anticancer drugs used in clinical practice today come from plants.

What are pharmaceuticals made from plants?

In place of the conventional method of inoculating animals for Cell Culture production, plant manufactured pharmaceuticals are pharmaceuticals derived from genetically modified plants used as therapeutic compounds.

What is a biopharming illustration?

Biopharming has a number of well-known applications, such as transgenic sheep that produce human?-1-antitrypsin in their milk (people lacking this enzyme develop emphysema) and crops that express attenuated antigenic fragments for particular pathogenic diseases (e.g. edible vaccines).

What kind of plant is biotechnology used in?

Genetics and genomics, marker-assisted selection (MAS), and transgenic (genetically modified) crops are examples of plant biotechnologies that aid in the development of new varieties and traits.

How do trees contribute to preserving the balance of the atmosphere?

During the process of photosynthesis, the forest’s green plants and trees absorb carbon dioxide from the air and release oxygen into the atmosphere, which is then inhaled by animals during respiration, which in turn releases carbon dioxide that the plants then absorb.

How do trees contribute to ecosystem services in relation to air and water pollution brought on by climate change?

They prevent greenhouse gas emissions and lower energy costs for building owners by, among other things, sequestering carbon, lowering air pollution and stormwater runoff, reducing winter winds, and cooling their surroundings in the summer through transpiration and shade.

In 250 words, describe how trees can protect the planet from climate change and global warming.

Every day, trees give us many benefits, including removing carbon dioxide from the air, storing carbon in the soil and trees, and releasing oxygen into the atmosphere as they grow.

In 100 words, describe how trees can protect the planet from climate change and global warming.

Trees (along with all plants) use sunlight energy to perform photosynthesis, which is a process that uses carbon dioxide and water to create energy (glucose) for their cells. As trees grow, they assist in absorbing and sinking the carbon that would otherwise contribute to global warming.

Short answer: Trees help to keep the balance of the atmosphere.

Additionally, trees store carbon dioxide in their fibers, which helps to purify the air and lessen any unfavorable effects this CO2 might have had on the environment.

To stop climate change, how many trees must be planted?

At this rate, 640 trees per person, or more than 200 billion trees, would be required to account for all American emissions, while a single mature tree may absorb about 50 pounds of carbon dioxide annually.

What tree should I plant in order to combat climate change?

The best plants are those with broad leaves, such as oak, beech, and maple, as opposed to conifers, which have smaller leaf surfaces that absorb more heat.

Share this post